Sponsored
⚡ News

Vagus Nerve Implant Reduces Inflammation in Rheumatoid Arthritis Patients in New Clinical Trial

Woman's neck with highlighted pain area

SetPoint Medical, a Valencia, California company built on research into the nerve that connects the brain to the immune system, has reported that its pivotal trial of an implanted vagus nerve stimulator met its primary goal in patients with rheumatoid arthritis. Patients who received active stimulation showed significantly better disease response than patients who got a sham version of the same implant. The trial, called RESET-RA, is the largest, most rigorously controlled test to date of an idea that has been circulating in labs since the late 1990s: that you can treat an autoimmune disease not with a drug, but with electricity delivered to a single nerve in the neck.

That idea sounds like a stretch until you look at where it came from. The science behind RESET-RA traces back to Kevin Tracey’s lab at the Feinstein Institutes for Medical Research on Long Island, where researchers found in the late 1990s that cutting a rat’s vagus nerve caused inflammation to spike, and stimulating it suppressed inflammation across the body. That discovery, published in Nature in 2000, described what Tracey later named the inflammatory reflex: a direct, fast-acting nerve circuit that the brain uses to keep immune activity in check, running in parallel to the slower chemical signaling of hormones and cytokines. Rheumatoid arthritis, a disease in which the immune system attacks the joints, turned out to be one of the more plausible targets for hijacking that circuit on purpose.

The Nerve That Talks to the Immune System

Here is the mechanism, stripped down. The vagus nerve runs from the brainstem down through the neck and into the chest and abdomen, touching the heart, lungs, and gut along the way. When it fires, one branch of signaling eventually reaches the spleen, where it triggers the release of acetylcholine. That acetylcholine binds to a receptor called alpha-7 nicotinic acetylcholine receptor, found on macrophages, the immune cells responsible for churning out tumor necrosis factor, or TNF-alpha, one of the central inflammatory molecules driving joint destruction in rheumatoid arthritis. Flip the switch on the nerve, and you turn down TNF production at the source, without a pill or an injection entering the bloodstream.

Stimulate the vagus, and the macrophages stop making as much TNF. No drug involved.

This is not a new theory tested for the first time in RESET-RA. In 2016, Frieda Koopman, a rheumatologist then at the Academic Medical Center in Amsterdam, published results in the Proceedings of the National Academy of Sciences showing that a small group of rheumatoid arthritis patients implanted with an early version of the device had reduced TNF production and measurable improvement in disease activity scores, with effects that persisted as long as the stimulation continued. Paul-Peter Tak, a co-author on that paper and a longtime rheumatology researcher, and David Chernoff, SetPoint’s chief medical officer, helped turn that pilot data into the foundation for a company and, eventually, a much larger trial designed to satisfy the FDA rather than just a journal’s reviewers.

The Device Is Boring On Purpose

You might picture a vagus nerve implant as something dramatic, on par with deep brain stimulation electrodes threaded into brain tissue. It isn’t. The SetPoint system is a small cuff electrode placed surgically around the cervical vagus nerve in the neck, connected to a lead and a battery-free receiver implanted just under the skin. Patients do not wear it constantly in the way a pacemaker runs continuously. Instead, they use an external controller, similar in concept to a charging pad, to deliver a short burst of stimulation, roughly a minute at a time, once or twice a day. Outside of that brief window, the device does nothing.

That dosing pattern is deliberate and it is also one of the more interesting engineering decisions in the whole program. Vagus nerve stimulators built for epilepsy and depression, made by companies like LivaNova, run near-continuously for years to prevent seizures or stabilize mood. SetPoint’s device is tuned for a different kind of biology: the inflammatory reflex appears to respond to brief, intermittent activation, and dialing it down to a minute or two daily reduces the device’s power demands, extends battery life, and avoids off-target effects on heart rate and digestion that longer stimulation can trigger. It is a reminder that “vagus nerve stimulation” is not one treatment. The target organ, the waveform, and the schedule all change depending on what disease you are trying to move.

Why a Pivotal Trial Matters More Than a Pilot Study

Small, open-label studies like the 2016 Amsterdam trial are useful for proving a concept works at all, but they are notoriously bad at ruling out placebo effects, especially in a disease like rheumatoid arthritis where patients self-report pain and function. RESET-RA was designed to close that gap: a randomized, multicenter, sham-controlled trial run across the United States, in which neither patients nor evaluating clinicians knew who was receiving active stimulation and who was getting an implant that did nothing. SetPoint announced in December 2023 that the trial met its primary endpoint, with patients on active stimulation achieving significantly higher ACR20 response rates, the standard rheumatology measure of a 20 percent improvement in disease activity, compared to the sham group.

A sham-controlled result is the difference between a promising idea and a credible one.

The target population matters here. A meaningful share of rheumatoid arthritis patients do not get adequate relief from methotrexate or from the first biologic drug they try, such as TNF inhibitors like adalimumab or etanercept, and cycling through additional biologics carries real costs, both financial and medical, since suppressing TNF systemically raises infection risk. A device that produces a similar anti-inflammatory effect through a localized nerve signal, rather than a drug circulating through the whole body, is appealing precisely because it narrows the exposure. That is the pitch SetPoint has made to the FDA, which granted the device Breakthrough Device Designation, a program meant to speed review for technologies addressing unmet medical need, rather than full market clearance.

Study Year Design Reported outcome
Koopman et al., PNAS 2016 Open-label pilot, Academic Medical Center Amsterdam Reduced TNF production, improved disease activity scores during active stimulation
RESET-RA, SetPoint Medical 2023 (topline) Randomized, multicenter, sham-controlled, double-blind Met primary endpoint: significantly higher ACR20 response versus sham

What the Data Doesn’t Tell You Yet

Here is the honest catch, and it is worth sitting with instead of skating past. As of this writing, the RESET-RA results have been announced by SetPoint Medical itself, in a company statement, not published in a peer-reviewed journal with full methods and complete numbers available for outside scrutiny. That distinction matters. Company topline announcements tend to emphasize the result that clears the regulatory bar and say less about secondary endpoints, dropout rates, or how durable the benefit is once you move past the initial trial window. Until the full dataset is published and reviewed, “met its primary endpoint” should be read as a real and promising claim, not a verified one.

There is also the matter of what this treatment actually asks of a patient. Getting the implant means surgery, with the attendant small risks of infection, nerve injury, and the general unpleasantness of having a foreign object placed around a nerve that also helps regulate your heart rate and digestion. It is a bigger commitment than swallowing a pill, and it is not reversible in the casual sense that stopping a drug is. Nobody has published long-term data on how the device performs after five or ten years, whether the anti-inflammatory effect fades, or whether the body’s immune response adapts to chronic intermittent stimulation the way it sometimes adapts to chronic drug exposure. None of that is a reason to dismiss the result. It is a reason not to treat “pivotal trial met its endpoint” as the end of the story.

A pill is reversible by Tuesday. An implant is a decision you live with.

There is a reimbursement question sitting underneath all of this too. Insurers know how to price a monthly biologic prescription. They have far less practice pricing a surgical implant plus a device plus follow-up programming, even when the long-run cost might be lower for a patient who would otherwise cycle through several expensive biologics that do not work. SetPoint’s trial proves the biology can hold up under a rigorous design. Getting a payer to write a check for the implant is a separate fight, and one that bioelectronic medicine companies, including the vagus nerve stimulator makers that came before them in epilepsy and depression, have historically found slower than the science itself.

What RESET-RA actually establishes is narrower than “a cure for rheumatoid arthritis” and more interesting than a company press release usually sounds. It establishes that a mechanism discovered in rats at a lab on Long Island twenty five years ago survived the jump into a randomized, blinded, sham-controlled human trial without falling apart, which is the exact point where a lot of promising bioelectronic ideas have historically failed. The open question now is not whether the vagus nerve can be dialed to quiet an autoimmune disease. It is whether the published full dataset holds up the same way the topline numbers do, and whether insurers decide an implant is worth paying for before a patient has cycled through every biologic on the shelf.

Credit: Sasun Bughdaryan on Unsplash

bioelectronic medicinebioelectronic medicine for autoimmune diseasecholinergic anti-inflammatory pathwayinflammatory reflexKevin Tracey inflammatory reflexrheumatoid arthritisSetPoint MedicalSetPoint Medical RESET-RA trialvagus nerve stimulationvagus nerve stimulation rheumatoid arthritis
Facebook
Twitter
LinkedIn
Stay charged
The electric pulse of discovery, in your inbox.

One weekly email. The most fascinating stories at the intersection of biology, electricity, and the future. No noise.